Filtered By:
Condition: Heart Valve Disease
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 554 results found since Jan 2013.
Preoperative Venoarterial Extracorporeal Membrane Oxygenation Slashes Risk Score in Advanced Structural Heart Disease
ConclusionsECMO can be used as a bridge to heart valve or septal defect surgery in severely decompensated patients. Through recovery of end-organ function, ECMO may allow surgical correction of structural heart disease in patients considered inoperable or convert a salvage situation to an elective operation.
Source: The Annals of Thoracic Surgery - September 18, 2018 Category: Cardiovascular & Thoracic Surgery Source Type: research
Preoperative Venoarterial Extracorporeal Membrane Oxygenation Slashes Risk Score in Advanced Structural Heart Disease.
CONCLUSIONS: ECMO can be used as a bridge to heart valve or septal defect surgery in severely decompensated patients. Through recovery of end-organ function, ECMO may allow surgical correction of structural heart disease in patients considered inoperable or convert a salvage situation to an elective operation.
PMID: 30236527 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - September 17, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Watkins AC, Maassel NL, Ghoreishi M, Dawood MY, Pham SM, Kon ZN, Taylor BS, Griffith BP, Gammie JS Tags: Ann Thorac Surg Source Type: research
MitraClip ® Implantation Under Cerebral Protection: A Case Report.
MitraClip® Implantation Under Cerebral Protection: A Case Report.
J Heart Valve Dis. 2017 Nov;26(6):728-730
Authors: Pohl J, Luedike P, Alexander Jánosi R, Rassaf T
Abstract
MitraClip® implantation is commonly used in patients with severe mitral regurgitation (MR) and who are at high risk for surgical mitral valve repair. The occurrence of stroke or transient ischemic attack is a potential complication in patients undergoing MitraClip implantation, and incidences of up to 2.6% have been reported. Herein is reported the case of an 84-year-old woman with severe MR and a thin filamentous structure at t...
Source: Journal of Heart Valve Disease - September 13, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research
Red Cell Distribution Width as a Prognostic Marker in Patients Undergoing Valve Surgery.
CONCLUSIONS: An elevated RDW is associated with a worse outcome following valve surgery. The predictive ability of the RDW, when assessed by the area under the ROC curve, improved the predictive ability of the EuroSCORE II calculator.
PMID: 30207123 [PubMed - in process]
Source: Journal of Heart Valve Disease - September 13, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research
Cardioembolic Stroke from an Atrial Myxoma in a Pediatric Patient: A Case Report and Review of the Literature.
Authors: Aldajani AA, Mudhry MA, Mir A, Albaradie RS
Abstract
Cardioembolic stroke is an uncommon phenomenon in pediatric patients. Although the heart is the usual source of the condition, cardiac myxomas are still considered to be a rare cause in children. The case is presented of a 13-year-old, right-handed Saudi boy who showed right-sided weakness for 30 h prior to hospital admission that involved the face, arm, and leg, with slurred speech. The patient had been discharged previously from a local hospital, without active management. An examination showed decreased strength on the right side, with hyperreflexia a...
Source: Journal of Heart Valve Disease - September 13, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research
Boston Scientific touts Acurate Neo2 CE Mark study
Boston Scientific (NYSE:BSX) yesterday touted results from a European study of the Acurate Neo2 replacement heart valve it acquired along with Symetis last year.
Thirty-day results from a 120-patient trial backing a bid for CE Mark approval for the transcatheter aortic valve replacement, acquired for $435 million in May 2017, were presented at the annual PCR London Valves conference, Marlborough, Mass.-based Boston Scientific said.
Patients treated in the single-arm study showed a 97% rate of mild or less-than-mild paravalvular leakage and a procedural success rate of 97.5%, the company said. All-cause mortality (the p...
Source: Mass Device - September 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Replacement Heart Valves Boston Scientific Source Type: news
INR Control of Patients with Mechanical Heart Valve on Long-Term Warfarin Therapy
ConclusionsDespite a majority of patients having <60% TTR, there were low incidences of bleeding and stroke events in this center. There were no factors found to be associated with INR control in this study.
Source: Global Heart - September 11, 2018 Category: Cardiology Source Type: research
MicroRNA 199a Is Downregulated in Patients After Coronary Artery Bypass Graft Surgery and Is Associated with Increased Levels of Sirtuin 1 (SIRT 1) Protein and Major Adverse Cardiovascular Events at 3-Year Follow-Up.
CONCLUSIONS Altered expression of miR-199a in myocardial tissue was found to be associated with SIRT 1 upregulation in patients with CAD undergoing CABG and was associated with an increased MACCEs rate at mid-term follow-up.
PMID: 30192743 [PubMed - in process]
Source: Medical Science Monitor - September 8, 2018 Category: Research Tags: Med Sci Monit Source Type: research
Boston Scientific closes $270m Claret Medical buy
Boston Scientific (NYSE:BSX) said yesterday that it closed the $270 million buyout of Claret Medical and its Sentinel device, including a $50 million earnout pegged to a reimbursement win that just came in.
Claret’s Sentinel device is designed to trap and remove debris dislodged during transcatheter aortic valve replacements to prevent stroke and other neurological damage. The deal, announced July 20, originally called for an up-front cash payment of $220 million plus the $50 million reimbursement milestone.
That milestone was reached when the Centers for Medicare & Medicaid Services granted a New Technology Add...
Source: Mass Device - August 3, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Replacement Heart Valves Wall Street Beat Boston Scientific Claret Medical Inc. Source Type: news
Abbott Makes Strong Statement in TMVR Space with SUMMIT
Abbott Laboratories has hit a substantial milestone in its plan to bring the Tendyne transcatheter mitral valve replacement (TMVR) system to the U.S. market. The Abbott Park, IL-based company said it has initiated SUMMIT, a pivotal clinical study of the TMVR system. Up to 1,010 patients will be enrolled in up to 80 sites in the pivotal trial.
Abbott said the investigational Tendyne device is the first and only mitral valve replacement that can be repositioned and fully retrieved, allowing the surgeon to precisely place the device during implantation, which could improve patient outcomes. Tendyne is a tri-leaflet, bioprost...
Source: MDDI - July 26, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Cardiovascular Source Type: news
Boston Scientific puts $270m on the table for Claret Medical
Boston Scientific (NYSE:BSX) said today that it agreed to pay as much as $270 million to acquire Claret and its Sentinel device.
Marlborough, Mass.-based Boston Scientific said the deal involves an ip-front cash payment of $220 million and another $50 million pegged to a reimbursement milestone. Claret’s Sentinel device is designed to trap and remove debris dislodged during transcatheter aortic valve replacements to prevent stroke and other neurological damage.
After landing CE Mark approval in the European Union in 2014, Santa Rosa, Calif.-based Claret won de novo clearance from the FDA last year for the Sentinel d...
Source: Mass Device - July 20, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Replacement Heart Valves Wall Street Beat Boston Scientific Claret Medical Inc. Source Type: news
Transfemoral Implantation of the Acurate neo for the Treatment of Aortic Regurgitation.
CONCLUSIONS: In a selected patient population, transfemoral TAVR using the Acurate neo transcatheter heart valve was successful in treating aortic regurgitation, significantly reduced left ventricular dimensions, and improved clinical symptoms.
PMID: 30012890 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - July 18, 2018 Category: Cardiology Tags: J Invasive Cardiol Source Type: research
A Review of Alternative Access for Transcatheter Aortic Valve Replacement
AbstractWith the advent of transcatheter aortic valve replacement (TAVR), appropriately selected intermediate-, high-, and extreme-risk patients with severe aortic stenosis (AS) are now offered a less invasive option compared to conventional surgery. In contemporary practice, TAVR is performed predominantly via a transfemoral arterial approach, whereby a transcatheter heart valve (THV) is delivered in a retrograde fashion through the iliofemoral arterial system and thoraco-abdominal aorta, into the native aortic valve annulus. While the majority of patients possess suitable anatomy for transfemoral arterial access, there i...
Source: Current Treatment Options in Cardiovascular Medicine - July 4, 2018 Category: Cardiology Source Type: research
Aortic Valve Predilatation with a Small Balloon, without Rapid Pacing, prior to Transfemoral Transcatheter Aortic Valve Replacement.
Conclusion: In TAVR, AVPD with a small, nonocclusive balloon can be safely performed. By avoiding rapid pacing, this technique may be a valid alternative to traditional BAV. Whether or not the use of APVD without rapid pacing translates into less periprocedural complications needs to be assessed in future studies.
PMID: 29854723 [PubMed - in process]
Source: Biomed Res - June 3, 2018 Category: Research Authors: Shivaraju A, Thilo C, Sawlani N, Ott I, Schunkert H, von Scheidt W, Kastrati A, Kasel AM Tags: Biomed Res Int Source Type: research
Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicenter registry.
CONCLUSIONS: Initial experience with the new self-expanding CoreValve Evolut R® 34 mm valve is characterized by high procedural success, excellent hemodynamic performance and a low early complication rate.
PMID: 29808820 [PubMed - as supplied by publisher]
Source: EuroIntervention - May 31, 2018 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
